Loading patent…
AssigneeRutgers, The State University of New Jersey
InventorsSkylar Chuang, KiBum Lee
Estimating the term…
Described herein are compositions and methods for treating various indications in a subject including, but not limited to, atherosclerosis, cardiovascular diseases, inflammation, chronic inflammatory diseases, wounds, and spinal cord injuries. In some embodiments, the compositions and methods comprise a modified macrophage or monocyte comprising surface-expressed CD47-targeted chimeric antigen receptor (CAR) proteins and lipid-based particles conjugated to a surface of the modified macrophage or monocyte, wherein the lipid-based particles comprise a β-cyclodextrin (β-CD). In some embodiments, the lipid-based particles comprise lipid nanoparticles (LNPs).
A modified macrophage or monocyte comprising:
A method of treating atherosclerosis in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
A method of treating cardiovascular disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
A method of treating inflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
A method of treating a chronic inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
A method of treating a wound in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
A method of treating a spinal cord injury in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising:
Dependencies are inferred from the claim text.